News for Dr. Reddy's Laboratories Limited (RDY)

On June 5, HSBC upgraded Dr. Reddy’s Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from INR1,235, citing an optimistic outlook for the company in terms of earnings potential and solid market standing. HSBC’s updated estimates for FY2026 to FY2028 take into account the shifting market tide for semaglutide and […]

Summary: Dr. Reddy's Laboratories (RDY) Q4 earnings beat estimates with a notable 20.1% revenue growth. Analysts' average price target suggests an 8.11%

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2025 Earnings Conference Call May 9, 2025 10:00 AM ETCompany ParticipantsRicha Periwal - Head, IR and...

**media[569574]**

**media[569571,569572]**

SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's') for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and regions and the United States (U.S.).

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased revenue. See why RDY stock is a Buy.

The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2025 Q3 earnings call.

Jan 23, 2025 / 02:00PM GMTOperator Ladies and gentlemen, good day, and welcome to the Quarter 3 FY25 Earnings Conference Call of Dr. Reddy's Laboratories Limite

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ETCompany ParticipantsRicha Periwal – Head-Investor...

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therape

Earnings call: Dr. Reddy's reports robust growth and strategic expansions

Nov 05, 2024 / 02:00PM GMTOperator Ladies and gentlemen, good day and welcome to the quarter two FY25 earnings conference call of Dr. Reddy's Laboratories Limit

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ETCompany ParticipantsRicha Periwal - Head of Investor...

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia ® and Xgeva ®

Amphastar Pharmaceuticals has seen significant growth since its IPO, with its stock price increasing over 500%. Learn more about AMPH stock here.

Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia ® & Xgeva ® in the U.S., Europe and UK

Dr. Reddy's Laboratories Limited (NYSE:NYSE:RDY) Q4 2024 Earnings Conference Call May 7, 2024 10:00 AM ETCompany ParticipantsRicha Periwal - Head of...